Prevalence of Pre-antiretroviral-Treatment Drug Resistance by Gender, Age, and Other Factors in HIV-Infected Individuals Initiating Therapy in Kenya, 2013-2014

Simple item page
dc.contributor.authorSilverman, Rachel A.en
dc.contributor.authorBeck, Ingrid A.en
dc.contributor.authorKiptinness, Catherineen
dc.contributor.authorLevine, Mollyen
dc.contributor.authorMilne, Ross S.en
dc.contributor.authorMcGrath, Christine J.en
dc.contributor.authorBii, Steveen
dc.contributor.authorRichardson, Barbra A.en
dc.contributor.authorJohn-Stewart, Grace C.en
dc.contributor.authorChohan, Bhavnaen
dc.contributor.authorSakr, Samah R.en
dc.contributor.authorKiarie, James N.en
dc.contributor.authorFrenkel, Lisa M.en
dc.contributor.authorChung, Michael H.en
dc.coverage.countryKenyaen
dc.date.accessioned2022-01-13T16:27:19Zen
dc.date.available2022-01-13T16:27:19Zen
dc.date.issued2017-12-15en
dc.date.updated2022-01-13T16:27:18Zen
dc.description.abstractBackground: Pre-antiretroviral-treatment drug resistance (PDR) is a predictor of human immunodeficiency virus (HIV) treatment failure. We determined PDR prevalence and correlates in a Kenyan cohort. Methods: We conducted a cross-sectional analysis of antiretroviral (ARV) treatment-eligible HIV-infected participants. PDR was defined as ≥2% mutant frequency in a participant's HIV quasispecies at pol codons K103N, Y181C, G190A, M184 V, or K65R by oligonucleotide ligation assay and Illumina sequencing. PDR prevalence was calculated by demographics and codon, stratifying by prior ARV experience. Poisson regression was used to estimate prevalence ratios. Results: PDR prevalences (95% confidence interval [CI]) in 815 ARV-naive adults, 136 ARV-experienced adults, and 36 predominantly ARV-naive children were 9.4% (7.5%-11.7%), 12.5% (7.5%-19.3%), and 2.8% (0.1%-14.5%), respectively. Median mutant frequency within an individual's HIV quasispecies was 67%. PDR prevalence in ARV-naive women 18-24 years old was 21.9% (9.3%-40.0%). Only age in females associated with PDR: A 5-year age decrease was associated with adjusted PDR prevalence ratio 1.20 (95% CI, 1.06-1.36; P = .004). Conclusions: The high PDR prevalence may warrant resistance testing and/or alternative ARVs in high HIV prevalence settings, with attention to young women, likely to have recent infection and higher rates of resistance. Clinical trials registration: NCT01898754.en
dc.description.versionPublished versionen
dc.format.extentPages 1569-1578en
dc.format.extent10 page(s)en
dc.format.mimetypeapplication/pdfen
dc.identifier.doihttps://doi.org/10.1093/infdis/jix544en
dc.identifier.eissn1537-6613en
dc.identifier.issn0022-1899en
dc.identifier.issue12en
dc.identifier.orcidSilverman, Rachel [0000-0003-3082-9664]en
dc.identifier.other4430536 (PII)en
dc.identifier.pmid29040633en
dc.identifier.urihttp://hdl.handle.net/10919/107610en
dc.identifier.volume216en
dc.language.isoenen
dc.publisherOxford University Pressen
dc.relation.urihttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000418720000012&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=930d57c9ac61a043676db62af60056c1en
dc.rightsIn Copyrighten
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/en
dc.subjectImmunologyen
dc.subjectInfectious Diseasesen
dc.subjectMicrobiologyen
dc.subjectPretreatment drug resistanceen
dc.subjecttransmitted drug resistanceen
dc.subjectHIVen
dc.subjectoligonucleotide ligation assayen
dc.subjectantiretroviral therapyen
dc.subjectSUB-SAHARAN AFRICAen
dc.subjectOLIGONUCLEOTIDE LIGATION ASSAYen
dc.subjectRESOURCE-LIMITED SETTINGSen
dc.subjectTREATMENT-NAIVEen
dc.subjectREVERSE-TRANSCRIPTASEen
dc.subjectVIROLOGICAL FAILUREen
dc.subjectTREATMENT PROGRAMen
dc.subjectADULTSen
dc.subjectCHILDRENen
dc.subjectTRANSMISSIONen
dc.subject06 Biological Sciencesen
dc.subject11 Medical and Health Sciencesen
dc.subject.meshHumansen
dc.subject.meshHIVen
dc.subject.meshHIV Infectionsen
dc.subject.meshPrevalenceen
dc.subject.meshCross-Sectional Studiesen
dc.subject.meshNucleic Acid Hybridizationen
dc.subject.meshSequence Analysis, DNAen
dc.subject.meshAge Factorsen
dc.subject.meshSex Factorsen
dc.subject.meshDrug Resistance, Viralen
dc.subject.meshGenotypeen
dc.subject.meshMutation, Missenseen
dc.subject.meshAdolescenten
dc.subject.meshAdulten
dc.subject.meshAgeden
dc.subject.meshMiddle Ageden
dc.subject.meshKenyaen
dc.subject.meshFemaleen
dc.subject.meshMaleen
dc.subject.meshpol Gene Products, Human Immunodeficiency Virusen
dc.subject.meshYoung Adulten
dc.subject.meshGenotyping Techniquesen
dc.titlePrevalence of Pre-antiretroviral-Treatment Drug Resistance by Gender, Age, and Other Factors in HIV-Infected Individuals Initiating Therapy in Kenya, 2013-2014en
dc.title.serialJournal of Infectious Diseasesen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten
dc.type.otherArticleen
dc.type.otherJournalen
dcterms.dateAccepted2017-10-07en
pubs.organisational-group/Virginia Techen
pubs.organisational-group/Virginia Tech/Veterinary Medicineen
pubs.organisational-group/Virginia Tech/Veterinary Medicine/Population Health Sciencesen
pubs.organisational-group/Virginia Tech/Faculty of Health Sciencesen

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
jix544.pdf
Size:
357.07 KB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections

All Faculty Deposits
Scholarly Works, Population Health Sciences